Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy

by Leanne G. Ahronian, Ryan B. Corcoran
Published 2017-04-01

Quantification of ongoing APOBEC3A activity in tumor cells by monitoring RNA editing at hotspots

by Pégah Jalili, Danae Bowen, Adam Langenbucher, Shinho Park, Kevin Aguirre, Ryan B. Corcoran, Angela G. Fleischman, Michael S. Lawrence, Lee Zou, Rémi Buisson
Published 2020-06-01

A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma

by Meghan J. Mooradian, Alexandre Reuben, Peter A. Prieto, Mehlika Hazar-Rethinam, Dennie T. Frederick, Brandon Nadres, Adriano Piris, Vikram Juneja, Zachary A. Cooper, Arlene H. Sharpe, Ryan B. Corcoran, Keith T. Flaherty, Donald P. Lawrence, Jennifer A. Wargo, Ryan J. Sullivan
Published 2018-05-01

Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis

by Sophia C. Kamran, Jeffrey W. Clark, Hui Zheng, Darrell R. Borger, Lawrence S. Blaszkowsky, Jill N. Allen, Eunice L. Kwak, Jennifer Y. Wo, Aparna R. Parikh, Ryan D. Nipp, Janet E. Murphy, Lipika Goyal, Andrew X. Zhu, A. John Iafrate, Ryan B. Corcoran, David P. Ryan, Theodore S. Hong
Published 2018-07-01

Resistance to checkpoint blockade therapy through inactivation of antigen presentation

by Moshe Sade-Feldman, Yunxin J. Jiao, Jonathan H. Chen, Michael S. Rooney, Michal Barzily-Rokni, Jean-Pierre Eliane, Stacey L. Bjorgaard, Marc R. Hammond, Hans Vitzthum, Shauna M. Blackmon, Dennie T. Frederick, Mehlika Hazar-Rethinam, Brandon A. Nadres, Emily E. Van Seventer, Sachet A. Shukla, Keren Yizhak, John P. Ray, Daniel Rosebrock, Dimitri Livitz, Viktor Adalsteinsson, Gad Getz, Lyn M. Duncan, Bo Li, Ryan B. Corcoran, Donald P. Lawrence, Anat Stemmer-Rachamimov, Genevieve M. Boland, Dan A. Landau, Keith T. Flaherty, Ryan J. Sullivan, Nir Hacohen
Published 2017-10-01